Compare Organon & Co. Common Stock (OGN) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Petróleo Brasileiro SA — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Petróleo Brasileiro SA trades at $25.95 (market cap $157.24B). The key difference: Petróleo Brasileiro SA is far larger — about 43.4× Organon & Co. Common Stock's market cap, and Petróleo Brasileiro SA pays the higher dividend (6.57%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Petróleo Brasileiro SA for 26 Days on average.
| OGN | PBR | |
|---|---|---|
Market Cap | $3.62B | $157.24B |
Volume | 2,892,999 | 17,564,454 |
Sector | Health | Energy |
52-Week High | $13.81 | $25.94 |
52-Week Low | $5.70 | $11.54 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $11.04B | $217.66B |
Dividend Yield | 0.58% | 6.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Petrobras (PBR) trades at $25.50, up 0.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings that beat estimates, with net income nearly doubling year-over-year on record production. Recent news highlights a new oil discovery off Amapa and a 22-year LNG supply deal with Cheniere Energy, supporting long-term growth prospects.
PBR presents a compelling value with a low P/E of 6.44 and robust profitability, including a 30.77% ROE. However, the stock trades above the analyst consensus price target of $22.33, and net cash flow turned negative in 2026. Key risks include political interference in Brazil, volatile oil prices, and execution challenges in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
